Inhibitory Potential of Shen-Shuai-Ling Formulation on Renal Interstitial Fibrosis via Upregulation of PLZF

Figure 4

SSLF and luteolin upregulation of PLZF levels. (a, b) Protein and gene expression of PLZF, PRR, Ang-1, Ang-2, and TGF-β. Western blot and qPCR analyses were performed after treatment with different concentrations of medicated rat serum containing SSLF. (c, d) Protein and gene expression of PLZF, PRR, Ang-1, Ang-2, and TGF-β. Western blot and qPCR analyses were performed after treatment with different concentrations of luteolin (5 μM, 10 μM, and 20 μM). Data are represented as mean ± SD (n ≥ 3 experiments).  < 0.05,  < 0.01,  < 0.001, and  < 0.0001 as determined using Student’s t-test (two groups) or one-way ANOVA, followed by Tukey’s test (more than two groups).

(a)

(b)

(c)

(d)